Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Grail, a US-Hong Kong Diagnostics Company, May Stage $500 Million Hong Kong IPO

publication date: Mar 1, 2018

Grail, a US spinout from Illumina that is developing blood-based cancer detection tests, is considering a $500 million Hong Kong IPO. Last year, Grail completed a $900 million Series B fundraising, the largest ever. In June, Grail merged with Cirina, a Hong Kong cancer diagnostics company, which was co-founded by Dennis Lo, DM, DPhil, an early scientific leader in the field of molecular diagnostics. Grail is considering Hong Kong for its IPO venue following new HKEX rules that allow companies to IPO even if they aren't profitable and to offer two classes of stock, one with voting rights (for the original owners) and one without. More details....

Stock Symbol: (NSDQ: ILMN)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China